• Users Online: 113
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 45  |  Issue : 2  |  Page : 92-96

A potential immunological diagnostic marker for acute myeloid leukemia: the expression of the immune checkpoint B and T lymphocyte attenuator

1 Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
2 Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
3 Department of Internal Medicine, Clinical Hematology Division, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4 Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Correspondence Address:
Nooran S Elleboudy
Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St. Abbassia, Cairo 11566
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejh.ejh_13_20

Rights and Permissions

Introduction Provided the physiologic tumor suppressive role a healthy immune system has, diagnosis of cancer is sometimes also regarded as a diagnosis of an immune dysfunction. Immunoediting refers to the change of immune system response from tumor protection to tumor promotion, favoring the growth of poorly immunogenic clones that have the ability to evade the immune response. Among the mechanisms by which the tumor cells bypass the immune system is immune checkpoints. Which are immune inhibitory pathways responsible for self-tolerance and limiting self-tissue damage by controlling the magnitude and duration of the immune reaction. Objective Studying the expression of the novel immune checkpoint BTLA in patients with AML and evaluate its clinicopathological and diagnostic significance. Patients and methods We investigated the expression of BTLA gene in 60 AML cases and 15 healthy controls using RT-PCR. Results The current study revealed that significant up regulation of BTLA mRNA expression in AML patients as in comparison with the control group (P=0.024). Discussion These results provide a basis for the perception that BTLA upregulation is involved in inhibition of antitumor immunity and that high BTLA expression level can be made use of as a diagnostic marker in patients with AML.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal